New study aims to personalize chemo dosing for blood cancer patients

NCT ID NCT05534620

First seen Jan 04, 2026 · Last updated May 08, 2026 · Updated 21 times

Summary

This study looks at how kidney function and race/ethnicity affect the way the drug treosulfan works in people with acute myeloid leukemia or myelodysplastic syndrome who are getting a stem cell transplant. The goal is to find the safest dose for those with kidney problems. About 36 participants will be enrolled.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MYELODYSPLASTIC SYNDROME (MDS) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Memorial Sloan Kettering Cancer Center

    WITHDRAWN

    New York, New York, 10021, United States

  • The Ohio State University

    RECRUITING

    Columbus, Ohio, 43210, United States

    Contact Email: •••••@•••••

  • University of Illinois

    RECRUITING

    Chicago, Illinois, 60612, United States

    Contact Email: •••••@•••••

  • VCU Massey Cancer Center

    RECRUITING

    Richmond, Virginia, 23298, United States

    Contact Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.